Thelansis

 Goodpasture’s Syndrome (GS) is a primarily sterile inflammatory neutrophilic dermatosis characterized by recurrent cutaneous ulcerations with mucopurulent or hemorrhagic exudate. ·        One estimate places the incidence of Goodpasture’s Syndrome (GS) at 1 in every 100,000 people in the United States Thelansis’s “Goodpasture’s Syndrome (GS) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Goodpasture’s Syndrome (GS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Goodpasture’s Syndrome (GS) across the 8 MM market from the centre of Excellence/ Public/ Private hospitals participat...

  Goodpasture’s syndrome (GS) is a rare, life-threatening, small vessel vasculitis that is mediated by circulating anti-glomerular basement membrane (anti-GBM) autoantibodies against the NC1 domain of the alpha 3 chain of type IV collagen, targeting capillaries of the kidneys and lungs. It is considered as one of the organ-specific autoimmune diseases that typically presents as rapidly progressive glomerulonephritis (RPGN), accompanied by alveolar hemorrhage with pathology characterized by crescentic glomerulonephritis with classic linear polyclonal immunoglobulin (Ig) G deposits on immunofluorescence staining of the GBM on analysis of kidney biopsy samples. Without prompt diagnosis and treatment, patients with GS can develop organ failure, resulting in significant morbidities and mortality. Patient characteristics included age, sex, race, year of hospitalization, smoking, hemoptysis, and the presence of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, which consi...